Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 5 studies | 26% ± 9% | |
goblet cell | 4 studies | 24% ± 5% | |
retina horizontal cell | 3 studies | 20% ± 3% | |
ciliated cell | 3 studies | 27% ± 7% | |
dendritic cell | 3 studies | 23% ± 4% | |
CD8-positive, alpha-beta T cell | 3 studies | 19% ± 3% | |
GABAergic neuron | 3 studies | 17% ± 2% | |
glutamatergic neuron | 3 studies | 23% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1972.89 | 1445 / 1445 | 100% | 25.80 | 183 / 183 |
intestine | 100% | 3664.89 | 966 / 966 | 100% | 23.53 | 527 / 527 |
ovary | 100% | 1380.48 | 180 / 180 | 100% | 23.06 | 430 / 430 |
stomach | 100% | 1714.55 | 359 / 359 | 100% | 25.30 | 286 / 286 |
uterus | 100% | 2377.11 | 170 / 170 | 100% | 20.14 | 459 / 459 |
lung | 100% | 2250.22 | 577 / 578 | 100% | 16.53 | 1155 / 1155 |
breast | 100% | 1494.93 | 459 / 459 | 100% | 17.21 | 1115 / 1118 |
bladder | 100% | 2034.10 | 21 / 21 | 100% | 19.84 | 502 / 504 |
pancreas | 100% | 1060.44 | 327 / 328 | 99% | 22.26 | 177 / 178 |
thymus | 100% | 1611.67 | 653 / 653 | 99% | 12.50 | 598 / 605 |
skin | 100% | 1683.09 | 1807 / 1809 | 96% | 16.11 | 454 / 472 |
kidney | 100% | 1155.83 | 89 / 89 | 96% | 14.79 | 864 / 901 |
prostate | 100% | 1564.05 | 245 / 245 | 95% | 8.31 | 479 / 502 |
adrenal gland | 100% | 1024.27 | 258 / 258 | 88% | 7.88 | 202 / 230 |
brain | 90% | 609.55 | 2369 / 2642 | 98% | 8.39 | 692 / 705 |
liver | 88% | 512.73 | 199 / 226 | 69% | 5.90 | 282 / 406 |
blood vessel | 100% | 2346.96 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 12.94 | 29 / 29 |
spleen | 100% | 2273.30 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.83 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.21 | 1 / 1 |
adipose | 100% | 1989.00 | 1203 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 2352.03 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2919.39 | 853 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 79% | 1061.17 | 737 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 65% | 4.37 | 52 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0007224 | Biological process | smoothened signaling pathway |
GO_0070885 | Biological process | negative regulation of calcineurin-NFAT signaling cascade |
GO_0006974 | Biological process | DNA damage response |
GO_0018107 | Biological process | peptidyl-threonine phosphorylation |
GO_0042771 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0045725 | Biological process | positive regulation of glycogen biosynthetic process |
GO_1901796 | Biological process | regulation of signal transduction by p53 class mediator |
GO_0006468 | Biological process | protein phosphorylation |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0005634 | Cellular component | nucleus |
GO_0004712 | Molecular function | protein serine/threonine/tyrosine kinase activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0000287 | Molecular function | magnesium ion binding |
GO_0030145 | Molecular function | manganese ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | DYRK2 |
Protein name | Dual specificity tyrosine phosphorylation regulated kinase 2 Alternative protein DYRK2 Dual specificity tyrosine-phosphorylation-regulated kinase 2 (EC 2.7.12.1) |
Synonyms | |
Description | FUNCTION: Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth. Functions in part via its role in ubiquitin-dependent proteasomal protein degradation. Functions downstream of ATM and phosphorylates p53/TP53 at 'Ser-46', and thereby contributes to the induction of apoptosis in response to DNA damage. Phosphorylates NFATC1, and thereby inhibits its accumulation in the nucleus and its transcription factor activity. Phosphorylates EIF2B5 at 'Ser-544', enabling its subsequent phosphorylation and inhibition by GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May play a general role in the priming of GSK3 substrates. Inactivates GYS1 by phosphorylation at 'Ser-641', and potentially also a second phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP E3 ligase complex formation and is required for the phosphorylation and subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', promoting TERT ubiquitination by the EDVP complex. Phosphorylates SIAH2, and thereby increases its ubiquitin ligase activity. Promotes the proteasomal degradation of MYC and JUN, and thereby regulates progress through the mitotic cell cycle and cell proliferation. Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a role in smoothened and sonic hedgehog signaling. Plays a role in cytoskeleton organization and neurite outgrowth via its phosphorylation of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro). . |
Accessions | ENST00000344096.4 [Q92630-1] A0A0A0MR56 F5H5L5 ENST00000393555.3 [Q92630-2] ENST00000542503.1 L8ECA4 ENST00000319833.6 F5GXG1 Q92630 ENST00000543747.1 |